Association of Cardiometabolic Multimorbidity With Mortality

作者：Emanuele Di Angelantonio, Stephen Kaptoge, David Wormser, Peter Willeit, Adam S. Butterworth, Narinder Bansal, Linda M. O’Keeffe, Pei Gao, Angela Wood, Stephen Burgess, Daniel F. Freitag, Lisa Pennells, Sanne A. E. Peters, Carole Hart, Lise Lund Håheim, Richard F. Gillum, Børge G. Nordestgaard, Bruce M. Psaty, Bu B. Yeap, Matthew Knuiman, Paul J. Nietert, Jussi Kauhanen, Jukka T. Salonen, Lewis H. Kuller, Leon A. Simons, Yvonne T. van der Schouw, Elizabeth Barrett‐Connor, Randi Selmer, Carlos J. Crespo, Beatriz L. Rodríguez, W. M. Monique Verschuren, Veikko Salomaa, Kurt Svärdsudd, Pim van der Harst, Cecilia Björkelund, Lars Wilhelmsen, Robert B. Wallace, Hermann Brenner, Philippe Amouyel, Elizabeth Barr, Hiroyasu Iso, Altan Onat, Maurizio Trevisan, Ralph B. D’Agostino, Cyrus Cooper, Maryam Kavousi, Lennart Welin, Ronan Roussel, Frank B. Hu, Shinichi Sato, Karina W. Davidson, Barbara V. Howard, Maarten J.G. Leening, Annika Rosengren, Marcus Dörr, Dorly J. H. Deeg, Stefan Kiechl, Coen D.A. Stehouwer, Aulikki Nissinen, Simona Giampaoli, Chiara Donfrancesco, Daan Kromhout, Jackie F. Price, Annette Peters, Tom Meade, Edoardo Casiglia, Debbie A. Lawlor, John Gallacher, Dorothea Nagel, Oscar H. Franco, Gerd Assmann, Gilles R. Dagenais, J. Wouter Jukema, Johan Sundström, Mark Woodward, Eric J. Brunner, Kay-Tee Khaw, Nicholas J. Wareham, Eric A. Whitsel, Inger Njølstad, Bo Hedblad, Sylvia Wassertheil‐Smoller, Gunnar Engström, Wayne D. Rosamond, Elizabeth Selvin, Naveed Sattar, Simon G. Thompson, John Danesh · 发表于：JAMA · 年份：2015 · DOI：10.1001/jama.2015.7008 · 被引用次数：1184 · 研究领域：Chronic Disease Management Strategies、Acute Myocardial Infarction Research、Diabetes, Cardiovascular Risks, and Lipoproteins

IMPORTANCE: The prevalence of cardiometabolic multimorbidity is increasing. OBJECTIVE: To estimate reductions in life expectancy associated with cardiometabolic multimorbidity. DESIGN, SETTING, AND PARTICIPANTS: Age- and sex-adjusted mortality rates and hazard ratios (HRs) were calculated using individual participant data from the Emerging Risk Factors Collaboration (689,300 participants; 91 cohorts; years of baseline surveys: 1960-2007; latest mortality follow-up: April 2013; 128,843 deaths). The HRs from the Emerging Risk Factors Collaboration were compared with those from the UK Biobank (499,808 participants; years of baseline surveys: 2006-2010; latest mortality follow-up: November 2013; 7995 deaths). Cumulative survival was estimated by applying calculated age-specific HRs for mortality to contemporary US age-specific death rates. EXPOSURES: A history of 2 or more of the following: diabetes mellitus, stroke, myocardial infarction (MI). MAIN OUTCOMES AND MEASURES: All-cause mortality and estimated reductions in life expectancy. RESULTS: In participants in the Emerging Risk Factors Collaboration without a history of diabetes, stroke, or MI at baseline (reference group), the all-cause mortality rate adjusted to the age of 60 years was 6.8 per 1000 person-years. Mortality rates per 1000 person-years were 15.6 in participants with a history of diabetes, 16.1 in those with stroke, 16.8 in those with MI, 32.0 in those with both diabetes and MI, 32.5 in those with both diabetes ...